Compare Nutanix Inc (NTNX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Novo Nordisk A/S — how do they compare? Nutanix Inc trades at $53.61 (market cap $14.90B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 14.8× Nutanix Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| NTNX | NVO | |
|---|---|---|
Market Cap | $14.90B | $220.53B |
Sector | Technology | Health |
52-Week High | $81.12 | $71.70 |
52-Week Low | $34.41 | $35.29 |
Enterprise Value | $14.41B | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
